



Featured Clinical Trials

Hematologic Malignancies, Stem Cell Transplantation and Cellular Therapies

Applicable Disease(s)/Treatment(s)	Study Description	Principal Investigator
Leukemia and Myelodysplasia		
Acute myeloid leukemia <i>Newly diagnosed</i>	A phase 3 randomized study of crenolanib versus midostaurin administered following induction chemotherapy and consolidation therapy in newly-diagnosed patients with FLT3-mutated acute myeloid leukemia Protocol #17-623	Richard Stone, MD richard_stone@dfci.harvard.edu 617-632-6028
Acute myeloid leukemia <i>Newly diagnosed or Relapsed/refractory</i> Myelodysplastic syndromes <i>High risk</i>	A phase 1 study of SL-401 in combination with azacitidine in relapsed/refractory acute myeloid leukemia (AML) or in treatment-naïve patients with AML not eligible for standard induction therapy, or in patients with high-risk myelodysplastic syndrome (MDS) Protocol #17-056	Andrew Lane, MD, PhD andrew_lane@dfci.harvard.edu 617-632-6028
Acute myeloid leukemia <i>Newly diagnosed</i>	A phase 1b study of venetoclax in combination with intensive induction and consolidation chemotherapy in treatment-naïve patients with acute myelogenous leukemia Protocol #18-351	Richard Stone, MD richard_stone@dfci.harvard.edu 617-632-6028
B-cell acute lymphoblastic leukemia <i>Newly diagnosed</i>	A phase 3 trial to evaluate the efficacy of the addition of inotuzumab ozogamicin (a conjugated anti-CD22 monoclonal antibody) to frontline therapy in young adults (ages 18-39 years) with newly-diagnosed precursor B-cell ALL Protocol #17-717	Daniel DeAngelo, MD, PhD daniel_deangelo@dfci.harvard.edu 617-632-6028
Acute myeloid leukemia Myelodysplastic syndromes <i>Relapsed/refractory</i>	A phase 1 study of ipilimumab in combination with decitabine in relapsed or refractory myelodysplastic syndrome/acute myeloid leukemia Protocol #17-717	Jacqueline Garcia, MD jacqueline_garcia@dfci.harvard.edu 617-632-6028
Acute myeloid leukemia Myelodysplastic syndromes MDS/MPN overlap syndrome <i>Relapsed/refractory</i>	A phase 1 study of venetoclax added to busulfan and fludarabine reduced-intensity conditioning regimen for AML, MDS, and MDS/MPN overlap syndromes Protocol #18-283	Jacqueline Garcia, MD jacqueline_garcia@dfci.harvard.edu 617-632-6028
Acute myeloid leukemia <i>Relapsed/refractory</i>	A phase 1 study of merestinib in combination with LY2874455 in relapsed or refractory acute myeloid leukemia Protocol #17-099	Jacqueline Garcia, MD jacqueline_garcia@dfci.harvard.edu 617-632-6028

Leukemia and Myelodysplasia (continued)

Acute lymphoblastic leukemia <i>Relapsed/refractory</i>	A phase 1b study of the combination of venetoclax with chemotherapy as frontline therapy in older patients and patients with relapsed or refractory acute lymphoblastic leukemia Protocol #16-648	Daniel DeAngelo, MD, PhD daniel_deangelo@dfci.harvard.edu 617-632-6028
B-cell acute lymphoblastic leukemia Chronic myeloid leukemia <i>Newly diagnosed or relapsed/refractory</i>	A phase 1 study of ABL001 in combination with dasatinib and prednisone in patients with BCR-ABL positive (BCRABL+) B-cell acute lymphoblastic leukemia (B-ALL) and chronic myeloid leukemia (CML) Protocol #18-170	Marlise Luskin, MD, MSCE marlise_luskin@dfci.harvard.edu 617-632-6028
Myeloid malignancies	A phase 1b/2 study to evaluate the safety and efficacy of APR-246 in combination with azacitidine for the treatment of TP53-mutant myeloid neoplasms Protocol #17-378	David Steensma, MD david_steensma@dfci.harvard.edu 617-632-6028

Lymphoma and CLL

Follicular lymphoma <i>Newly diagnosed or Previously treated</i>	A multi-cohort phase 1b clinical trial of rituximab in combination with immunotherapy in untreated and previously-treated follicular lymphoma Protocol #18-311	Caron Jacobson, MD caron_jacobson@dfci.harvard.edu 617-632-6246
Histiocyte/dendritic neoplasms Aggressive lymphomas <i>Relapsed/refractory</i>	A phase 2 study of pembrolizumab in patients with histiocyte/dendritic cell neoplasms and biologically selected subtypes of relapsed/refractory aggressive lymphomas Protocol #17-448	Eric Jacobsen, MD eric_jacobsen@dfci.harvard.edu 617-632-6246
Chronic lymphocytic leukemia Small lymphocytic lymphoma <i>Newly diagnosed</i>	A phase 2 study of acalabrutinib, venetoclax, and obinutuzumab (AVO) for initial therapy of chronic lymphocytic leukemia Protocol #18-226	Matthew Davids, MD, MMSc matthew_davids@dfci.harvard.edu 617-632-6246
Chronic lymphocytic leukemia Small lymphocytic lymphoma <i>Relapsed/refractory</i>	A phase 1/2 study of duvelisib and venetoclax in patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma Protocol #18-089	Matthew Davids, MD, MMSc matthew_davids@dfci.harvard.edu 617-632-6246
B-cell malignancies <i>Relapsed/refractory</i>	A phase 1, open-label study of voruciclib in patients with relapsed and/or refractory B-cell malignancies after failure of prior standard therapies Protocol #18-164	Matthew Davids, MD, MMSc matthew_davids@dfci.harvard.edu 617-632-6246
Hematologic malignancies <i>Relapsed/refractory</i>	A phase 1, open-label, multicenter study to assess the safety, tolerability, pharmacokinetics and preliminary antitumor activity of ascending doses of AZD5991 in patients with relapsed or refractory hematologic malignancies Protocol #17-558	Matthew Davids, MD, MMSc matthew_davids@dfci.harvard.edu 617-632-6246
Richter's syndrome <i>Relapsed/refractory</i>	CRC043: A phase 2 study of venetoclax in combination with dose-adjusted EPOCH-R for the therapy of patients with Richter's syndrome Protocol #16-596	Matthew Davids, MD, MMSc matthew_davids@dfci.harvard.edu 617-632-6246
B-cell lymphoid malignancies <i>Relapsed/refractory to BTK inhibitor</i>	A phase 1b/2 dose-escalation and cohort-expansion study of the noncovalent, reversible Bruton's tyrosine kinase inhibitor, SNS-062, in patients with B-lymphoid malignancies Protocol #17-139	Jennifer Brown, MD, PhD jennifer_brown@dfci.harvard.edu 617-632-6246

Multiple Myeloma		
Monoclonal gammopathy of undetermined significance (MGUS) Smoldering multiple myeloma	A phase 2 study of the CD38-antibody daratumumab in patients with high-risk MGUS and low-risk smoldering multiple myeloma Protocol #17-212	Irene Ghobrial, MD irene_ghobrial@dfci.harvard.edu 617-632-3823
Multiple myeloma <i>Relapsed/refractory</i>	An open-label, multicenter, dose escalation/expansion phase 1b study to evaluate safety, pharmacokinetics, and activity of BET-inhibitor RO6870810, given as mono- and combination therapy to patients with advanced multiple myeloma Protocol #17-404	Jacob Laubach, MD, MPP jacobp_laubach@dfci.harvard.edu 617-632-3823
Multiple myeloma <i>Relapsed/refractory</i>	A phase 1 multicenter, open-label study to assess the safety, pharmacokinetics and preliminary efficacy of CC-92480 in combination with dexamethasone in patients with relapsed and refractory multiple myeloma Protocol #17-653	Paul Richardson, MD paul_richardson@dfci.harvard.edu 617-632-3823
Multiple myeloma <i>Relapsed/refractory</i>	A phase 1/ 2 study of pomalidomide, dexamethasone, and ixazomib vs. pomalidomide and dexamethasone for patients with multiple myeloma relapsing on lenalidomide as part of first-line therapy Protocol #14-334	Paul Richardson, MD paul_richardson@dfci.harvard.edu 617-632-3823
Multiple myeloma <i>Relapsed/refractory</i>	A randomized, controlled, open-label, phase 3 study of melflufen/ dexamethasone compared with pomalidomide/ dexamethasone for patients with relapsed/refractory multiple myeloma who are refractory to lenalidomide Protocol #17-224	Paul Richardson, MD paul_richardson@dfci.harvard.edu 617-632-3823
Multiple myeloma <i>Relapsed/refractory</i>	A single-arm, open-label, phase 2 study of melflufen in combination with dexamethasone in patients with relapsed refractory multiple myeloma who are refractory to pomalidomide and/or daratumumab Protocol #17-259	Paul Richardson, MD paul_richardson@dfci.harvard.edu 617-632-3823
Multiple myeloma <i>Relapsed/refractory</i>	A phase 1b study of SAR650984 (anti-CD38 mAb) in combination with pomalidomide and dexamethasone for the treatment of relapsed/refractory multiple myeloma Protocol #14-539	Paul Richardson, MD paul_richardson@dfci.harvard.edu 617-632-3823
Waldenström's Macroglobulinemia		
Waldenström's macroglobulinemia <i>Relapsed/refractory</i>	A phase 2 study of daratumumab in patients with relapsed or refractory Waldenström's macroglobulinemia Protocol #17-164	Jorge Castillo, MD jorgej_castillo@dfci.harvard.edu 617-632-3823
Waldenström's macroglobulinemia	A phase 1/2 study of ulocuplumab and ibrutinib in symptomatic patients with mutated CXCR4 Waldenström's macroglobulinemia Protocol #17-235	Steven Treon, MD, PhD steven_treon@dfci.harvard.edu 617-632-3823
Stem Cell Transplantation		
Graft-versus-host disease treatment and prevention	A randomized phase 2 study of obinutuzumab for prevention of chronic graft-versus-host disease after allogeneic peripheral blood stem cell transplantation Protocol #16-589	Corey Cutler, MD MPH corey_cutler@dfci.harvard.edu 617-632-6028
Graft-versus-host disease treatment and prevention	A phase 1b/2 open-label study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of AMG 592 in adult patients with steroid refractory chronic graft-versus-host disease Protocol #18-700	John Koreth, MBBS, DPhil john_koreth@dfci.harvard.edu 617-632-6028
(continued on back)		

Stem Cell Transplantation (continued)

Manipulated umbilical cord blood stem cells	A multicenter, randomized, phase 3 registration trial of transplantation of NiCord®, ex vivo expanded, umbilical cord blood-derived, stem and progenitor cells, versus unmanipulated umbilical cord blood for patients with hematological malignancies Protocol #17-252	Corey Cutler, MD, MPH corey_cutler@dfci.harvard.edu 617-632-6028
Ex vivo programmed peripheral blood stem cells	A phase 1, non-randomized, open-label/phase 2 randomized, blinded study of ProTmune (ex vivo programmed mobilized peripheral blood cells) versus non-programmed mobilized peripheral blood cells for allogeneic hematopoietic cell transplantation in adult patients with hematologic malignancies Protocol #17-387	Corey Cutler, MD, MPH corey_cutler@dfci.harvard.edu 617-632-6028

Cellular Therapies — CAR T Cell

Multiple myeloma <i>Relapsed/refractory</i>	A phase 1 study of bb2121 in BCMA-expressing multiple myeloma Protocol #16-054	Nikhil Munshi, MD nikhil_munshi@dfci.harvard.edu 617-632-3823
Multiple myeloma <i>Relapsed/refractory</i>	A phase 2, multicenter study to determine the efficacy and safety of bb2121 in patients with relapsed and refractory multiple myeloma Protocol #17-652	Nikhil Munshi, MD nikhil_munshi@dfci.harvard.edu 617-632-3823
Acute lymphoblastic leukemia <i>Relapsed/refractory</i>	A phase 1/2 multicenter study evaluating the safety and efficacy of KTE-C19 in adult patients with relapsed/refractory B-precursor acute lymphoblastic leukemia (ZUMA-3) Protocol #16-271	Daniel DeAngelo, MD, PhD daniel_deangelo@dfci.harvard.edu 617-632-6028
Indolent non-Hodgkin lymphoma <i>Relapsed/refractory</i>	A phase 2 multicenter study of axicabtagene ciloleucel in patients with relapsed/refractory indolent non-Hodgkin lymphoma (ZUMA-5) Protocol #17-075	Caron Jacobson, MD caron_jacobson@dfci.harvard.edu 617-632-6246
Large B-cell lymphoma <i>Relapsed/refractory</i>	A multicenter, open-label, expanded access study of axicabtagene ciloleucel for the of patients with relapsed/refractory large B-cell lymphoma Protocol #17-125	Caron Jacobson, MD caron_jacobson@dfci.harvard.edu 617-632-6246
Large B-cell lymphoma <i>Relapsed/refractory</i>	A phase 3, randomized, open label study evaluating the efficacy of axicabtagene ciloleucel versus standard of care therapy in patients with relapsed/refractory diffuse large B cell lymphoma (ZUMA-7) Protocol #17-541	Caron Jacobson, MD caron_jacobson@dfci.harvard.edu 617-632-6246

The above-listed trials are a sampling of our many open and accruing studies. If you are interested in, or would like more information about, a clinical trial listed here, please contact the principal investigator.

For a broader listing of our treatment protocols, please visit dfbwc.org/clinicaltrials.

These trials are conducted through Dana-Farber/Harvard Cancer Center, an NCI-designated Comprehensive Cancer Center.